It's harder and harder to tell reality from satire.

FLASHBACK FORWARD
#ATTRACTION05 adj nivo for LA #GEA

HR RFS 0.87 NS; HR OS 0.88 NS

PDL1 TPS >1% (freq 13.8%) HR RFS 0.33
PDL1 TPS <1% HR RFS 1.06

CPS-10?
MSI-H?

ascopubs.org/doi/abs/10.120…

FLASHBACK FORWARD
#CM577 adj nivo after CRT->S for LA GEA/esoSCC:

Adeno (freq 71%) HR DFS 0.75
SCC HR DFS 0.61

PDL1 CPS>5 (AC+SCC) (freq 55.7%) HR DFS 0.62
PDL1 CPS<5 (AC+SCC) HR DFS 0.89

Await data maturity for OS.
DFS/OS by CPS-10 by AC/SCC?

nejm.org/doi/full/10.10…

#KN585 periop chemo+/-pembro for LA #GEA

MSI-H (freq 9%) HR OS 0.46; MSS HR OS 0.99
PDL1>10 (freq 28.6%) HR OS 0.78; PDL1<10 HR OS 0.96
thelancet.com/journals/lanon…

ORIENT-16 sintilimab anti-PD1 plus chemo first line #GEA

jamanetwork.com/journals/jama/…

New research - Reynolds et al - Trimodality therapy vs perioperative chemotherapy for locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction: the Neo-AEGIS phase 3 trial

thelancet.com/journals/langa…

#OncTwitter #GITwitter #EsoCSM

Excited to share our publication in JAMA Oncology in which we show that the addition of ipi to nivo in non-melanoma solid tumors does not meaningfully increase PFS and OS jamanetwork.com/journals/jamao…

Lurie Cancer Center Northwestern Medicine Northwestern Feinberg School of Medicine

A drug w proven efficacy (in 2 separate ph3 trials) takes longer to get to pts than drugs with relatively scant data thru accelerated approval. Should +ve ph3 data get “accelerated approval” while also being reviewed for full approval?

astellas.com/en/news/27946?…

VESTIGE: Adjuvant immunotherapy in pts with resected GEA following preoperative chemotherapy with high risk for recurrence presented by Lizzy Smyth at #WCGIC2023
🔎EORTC phs II study
unfortunately⛔️
👉Adj. Nivo/IPI did not improve DFS & OS compared to CTx
ESMO - Eur. Oncology World Congress on Gastrointestinal Cancer

Looking forward to seeing the KEYNOTE 811 results at #ESMO 2023

✅ PFS endpoint met for **PD-L1 ➕ only**
❓OS.. trend but not there yet...

FDA label being amended for PD-L1 status; EMA right to wait?

The use of margituximab + pembrolizumab along with ctDNA used as a predictive biomarker for patients with pretreated HER2+ gastric/ gastroesophageal adenocarcinoma was analyzed by Daniel V. T. Catenacci, MD, et al. #gicsm | Howard S Hochster MD Daniel Catenacci

ow.ly/3Q8P50O2vES

SPOTLIGHT study of #Zolbetuximab was just published in The Lancet. Achievement by global collaboration to establish new treatment option for #gastriccancer . thelancet.com/journals/lance… ILSON David Manish A. Shah Florian Lordick Sam Klempner Astellas Pharma US OncoAlert ASCO ESMO - Eur. Oncology

Another day, another practice-changing trial in gastric cancer 👏👏👏

Thanks to ESMO - Eur. Oncology for allowing me to discuss KEYNOTE 859 with Florian Lordick & Brian Henick

➡️KEYNOTE-859 met the OS primary endpoint in the ITT (all-comer population)

As usual, excellent discussion from Lizzy Smyth. ESMO - Eur. Oncology plenary of Keynote-859.

Mike Pishvaian This is a very polite twitter feed. Nalirifox is NOT a NEW standard of care. It's just fancy FOLFIRINOX. That costs more and causes more diarrhea. Time to move on to some advances. We'll get there, advances are coming in PDAC beyond FFX.

Is it obvious??

#SPOTLIGHT HER2-/Claudin+
HR 0.75

#CM649 HER2-
HR 0.78

#CM649 HER2-/PDL1 CPS>10
HR 0.66

#CM649 HER2-/PDL1 CPS<10
HR 0.91
—————————————-

HER2-/PDL1 CPS>10= FOLFOX-Nivo

HER2-/PDL1 CPS<10/claudin+= FOLFOX-zolbe

HER2-/PDL1 CPS<10/claudin- = FOLFOX

#GEAwesome